The FDA Just Proposed Ending Mass GLP-1 Compounding — Here's What It Actually Means
Published: May 1, 2026 · 5 min read · By Grey Peptides News Desk · ✓ Sourced
On April 30, 2026, the FDA proposed a rule that would permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the regulatory mechanism that lets large outsourcing facilities compound from bulk active ingredients. If finalized, it closes the last remaining pathway for mass compounding of GLP-1s, regardless of any future shortage. Patient-specific 503A compounding remains legal.
The mechanism behind the policy
Federal law lets compounders work with bulk drug substances in only two situations: when the substance is on the 503B bulks list, or when the corresponding finished drug is on the FDA shortage list. Semaglutide and tirzepatide ran on the second pathway from 2022 until late 2024 and early 2025, when the FDA declared both shortages resolved. The Outsourcing Facilities Association sued. Federal courts declined to grant preliminary injunctions, and the enforcement deadlines held.
The April 30 proposal closes the other door. By formally finding "no clinical need" for any of the three drugs on the 503B bulks list, the FDA removes the only remaining route for outsourcing facilities to mass-compound them — even if a future shortage is declared. The proposal lives in the May 1 Federal Register notice, and the public comment period runs through June 29, 2026.
What this doesn't change (yet)
The headlines have been loose with the word "ban." This is not one. Two things continue to be legal under the proposed rule as written:
503A patient-specific compounding still operates under different rules and is not directly affected. State-licensed pharmacies can continue to prepare individualized formulations for specific patients with a valid prescription. Whether the FDA will eventually move against 503A "essentially a copy" compounding of GLP-1s is a separate fight — and one the agency has been signaling with warning letters, not yet with rules.
Liraglutide injection remains on the FDA shortage list. So even with the new proposal, 503B compounders can still work with it until the shortage is resolved — a strange artifact of the rule being technically in force for a drug that's still legally compoundable.
What does end, if this is finalized, is the business model that turned compounding telehealth into a billion-dollar category — mass production of injectable semaglutide and tirzepatide at $150 to $300 per month while branded versions ran above $1,000.
What we'd actually watch
Three things matter more than the headline noise:
The 503A guidance. If the FDA later restricts patient-specific GLP-1 compounding — particularly bundling supplemental ingredients like B12 to claim "significant difference" under the 2018 guidance — that's when the consumer market actually shifts. The April 30 proposal doesn't do that.
The salt-form question. The FDA has been explicit that semaglutide sodium and semaglutide acetate are not the same active ingredient as approved semaglutide and have no lawful basis for use in compounding. Enforcement against vendors selling salt forms is the more immediate quality issue.
What 503A pharmacies do next. Once 503B is closed and the FDA can credibly threaten 503A copy-compounding, telehealth companies will need to switch patients to branded products, exit the category, or test the FDA's enforcement appetite. Several have already started the switch.
Related on Grey Peptides
Country-by-country legal status of common peptides. How to Evaluate a Peptide Vendor
The 20-criterion vendor framework — relevant for compounded as well as research-grade products. Semaglutide — Encyclopedia entry
FDA-approved formulations, mechanism, and the four current Wegovy/Ozempic product lines.
FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List ↗
Federal Register Notice 91 Fed. Reg. 23431 (May 1, 2026). Comment period closes June 29, 2026.